Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database

database[Title] 2025-04-20

Summary:

CONCLUSIONS: The study highlights the importance of monitoring for the occurrence of hypogammaglobulinemia and infections in patients receiving ocrelizumab, ofatumumab and rituximab for MS. These ADRs can be extremely serious and highlight the need for ongoing research to optimize their safety profiles.

Link:

https://pubmed.ncbi.nlm.nih.gov/40235349/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=12QQbiNmM99eUQGIX1JjHIKcROC1Vzv4sOS-2S_LNI19uG_Yrk&fc=20220129225649&ff=20250420153021&v=2.18.0.post9+e462414

From feeds:

📚BioDBS Bibliography » database[Title]

Authors:

Raffaella Di Napoli, Nunzia Balzano, Concetta Rafaniello, Paola Della Monica, Marina Di Domenico, Daniele Di Giulio Cesare, Giorgia Teresa Maniscalco, Cristina Scavone, Ugo Trama

Date tagged:

04/20/2025, 15:30

Date published:

04/16/2025, 06:00